These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23776364)

  • 1. Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
    Dhimolea E
    Appl Clin Genet; 2011; 4():21-7. PubMed ID: 23776364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
    Church LD; Savic S; McDermott MF
    Biologics; 2008 Dec; 2(4):733-42. PubMed ID: 19707454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes.
    Bachove I; Chang C
    Open Access Rheumatol; 2014; 6():15-25. PubMed ID: 27790031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
    Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cryopyrin-associated periodic syndrome].
    Kümmerle-Deschner JB
    Z Rheumatol; 2012 Apr; 71(3):199-208. PubMed ID: 22527214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.
    Kuemmerle-Deschner JB; Haug I
    Ther Adv Musculoskelet Dis; 2013 Dec; 5(6):315-29. PubMed ID: 24294305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease.
    Kuemmerle-Deschner JB
    Semin Immunopathol; 2015 Jul; 37(4):377-85. PubMed ID: 25963520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Modeling of NLRP3 Identifies Enhanced ATP Binding and Multimerization in Cryopyrin-Associated Periodic Syndromes.
    Samson JM; Ravindran Menon D; Vaddi PK; Kalani Williams N; Domenico J; Zhai Z; Backos DS; Fujita M
    Front Immunol; 2020; 11():584364. PubMed ID: 33329557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cryopyrin-associated periodic syndromes].
    Quartier P; Rodrigues F; Georgin-Lavialle S
    Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rilonacept in the treatment of chronic inflammatory disorders.
    McDermott MF
    Drugs Today (Barc); 2009 Jun; 45(6):423-30. PubMed ID: 19649332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
    Welzel T; Kuemmerle-Deschner JB
    J Clin Med; 2021 Jan; 10(1):. PubMed ID: 33401496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
    Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
    Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts.
    Sarrabay G; Grandemange S; Touitou I
    Expert Rev Clin Immunol; 2015; 11(7):827-35. PubMed ID: 25979514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetics of cryopyrin-associated periodic syndrome].
    Kümmerle-Deschner JB; Lohse P
    Z Rheumatol; 2017 May; 76(4):313-321. PubMed ID: 28197772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).
    Gillespie J; Mathews R; McDermott MF
    J Inflamm Res; 2010; 3():1-8. PubMed ID: 22096352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Mutation negative" familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies.
    Hedrich CM; Bruck N; Paul D; Hahn G; Gahr M; Rösen-Wolff A
    Rheumatol Int; 2012 Sep; 32(9):2629-36. PubMed ID: 21833523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.